Barve R A, Minnerly J C, Weiss D J, Meyer D M, Aguiar D J, Sullivan P M, Weinrich S L, Head R D
Molecular Pharmacology Group, Pfizer Global Research and Development, St. Louis, MO, USA.
Osteoarthritis Cartilage. 2007 Oct;15(10):1190-8. doi: 10.1016/j.joca.2007.03.014. Epub 2007 May 14.
The objective of this study was to characterize the rat monosodium iodoacetate (MIA)-induced model for osteoarthritis (OA) and determine the translatability of this model to human disease. This was accomplished through pathway, network and system level comparisons of transcriptional profiles generated from animal and human disease cartilage.
An OA phenotype was induced in rat femorotibial joints following a single injection of 200mug MIA per knee joint for a period of 2 or 4 weeks. Lesion formation in the rat joints was confirmed by histology. Gene expression changes were measured using the Agilent rat whole genome microarrays. Cartilage was harvested from human knees and gene expression changes were measured using the Agilent human arrays.
One thousand nine hundred and forty-three oligos were differentially expressed in the MIA model, of these, approximately two-thirds were up-regulated. In contrast, of the 2130 differentially expressed oligos in human disease tissue, approximately two-thirds were down-regulated. This dramatic difference was observed throughout each level of the comparison. The total overlap of genes modulated in the same direction between rat and human was less than 4%. Matrix degradation and inflammatory genes were differentially regulated to a much greater extent in MIA than human disease tissue.
This study demonstrated, through multiple levels of analysis, that little transcriptional similarity exists between rat MIA and human OA derived cartilage. As disease modulatory activities for potential therapeutic agents often do not translate from animal models to human disease, this and like studies may provide a basis for understanding the discrepancies.
本研究的目的是描述大鼠碘乙酸钠(MIA)诱导的骨关节炎(OA)模型,并确定该模型与人类疾病的可转化性。这是通过对动物和人类疾病软骨产生的转录谱进行通路、网络和系统水平的比较来实现的。
在大鼠股骨胫关节单次注射每膝关节200μg MIA,持续2或4周,诱导OA表型。通过组织学证实大鼠关节中的病变形成。使用安捷伦大鼠全基因组微阵列测量基因表达变化。从人膝关节采集软骨,并使用安捷伦人类阵列测量基因表达变化。
在MIA模型中有1943个寡核苷酸差异表达,其中约三分之二上调。相比之下,在人类疾病组织中2130个差异表达的寡核苷酸中,约三分之二下调。在比较的每个水平上都观察到了这种显著差异。大鼠和人类中在相同方向上调的基因总重叠率不到4%。与人类疾病组织相比,MIA中基质降解和炎症基因的差异调节程度要大得多。
本研究通过多层次分析表明,大鼠MIA和人类OA来源的软骨之间几乎没有转录相似性。由于潜在治疗药物的疾病调节活性通常不能从动物模型转化到人类疾病,本研究及类似研究可能为理解这些差异提供基础。